Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) is a viable alternative to liver biopsy for steatosis quantification in living liver donor transplantation.
MRI-PDFF
donor liver steatosis
liver transplant
living liver donor
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
13
04
2021
received:
08
02
2021
accepted:
21
04
2021
pubmed:
9
5
2021
medline:
23
7
2021
entrez:
8
5
2021
Statut:
ppublish
Résumé
This study aimed to investigate whether magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) can be a viable noninvasive alternative to liver biopsy for the quantification of living liver donor steatosis. Hepatic steatosis for 143 donors was graded by MRI-PDFF. Study endpoints included liver volume regeneration in donors, recipient outcomes including length of hospital stay, deaths, primary non-function (PNF), early allograft dysfunction (EAD), and small for size syndrome (SFSS). Correlation between MRI-PDFF determined donor steatosis and endpoints were analyzed. Donors had lower steatosis grade than non-donors. Donor remnant liver regenerated to an average of 82% of pre-donation volume by 101 ± 24 days with no complications. There was no correlation between percent liver regeneration and steatosis severity. Among recipients, 4 underwent redo-transplantation and 6 died, with no association with degree of steatosis. 52 recipients (36%) fulfilled criteria for EAD (driven by INR), with no difference in hepatic steatosis between groups. MRI-PDFF reliably predicted donor outcomes. Living donors with no or mild steatosis based on MRI-PDFF (ie, <20%) and meeting other criteria for donation can expect favorable post-surgical outcomes, including liver regeneration. Recipients had a low rate of death or retransplantation with no association between mild hepatic steatosis and EAD.
Substances chimiques
Protons
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14339Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Kwong A, Kim W, Lake J, et al. OPTN/SRTR 2018 annual data report: liver. Am J Transplant. 2020;20:193-299.
Croome KP, Lee DD, Taner CB. The "Skinny" on assessment and utilization of steatotic liver grafts: a systematic review. Liver Transplant. 2019;25(3):488-499.
Vodkin I, Kuo A. Extended criteria donors in liver transplantation. Clin Liver Dis. 2017;21(2):289-301.
Chen Y-S, Cheng Y-F, de Villa VH, et al. Evaluation of living liver donors1. Transplantation. 2003;75(3):S16-S19.
McCormack L, Clavien PA. Understanding the meaning of fat in the liver. Liver Transpl. 2005;11(2):137-139.
Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239(1):105-112.
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49(3):1017-1044.
Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68(2):763-772.
Tang A, Desai A, Hamilton G, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology. 2015;274(2):416-425.
Idilman IS, Aniktar H, Idilman R, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology. 2013;267(3):767-775.
Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36(1):22-29.
Kramer H, Pickhardt PJ, Kliewer MA, et al. Accuracy of liver fat quantification with advanced CT, MRI, and ultrasound techniques: prospective comparison with MR spectroscopy. Am J Roentgenol. 2017;208(1):92-100.
Ajmera V, Park CC, Caussy C, et al. Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155(2):307-310.e2.
Stine JG, Munaganuru N, Barnard A, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020. https://doi.org/10.1016/j.cgh.2020.08.061. In press.
Kang GH, Cruite I, Shiehmorteza M, et al. Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J Magn Reson Imaging. 2011;34(4):928-934.
Middleton MS, Van Natta ML, Heba ER, et al. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology. 2018;67(3):858-872.
Noureddin M, Lam J, Peterson MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58(6):1930-1940.
Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598-607.e2.
Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant. 2005;5(11):2605-2610.
Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transplant. 2010;16(8):943-949.
Zamboni F, Franchello A, David E, et al. Effect of macrovescicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant. 2001;15(1):53-57.
Trotter JF, Wisniewski KA, Terrault NA, et al. Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology. 2007;46(5):1476-1484.
Hegarty J, Williams R. Liver biopsy: techniques, clinical applications, and complications. BMJ (Clin Res Ed). 1984;288(6426):1254.
Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol. 1999;5(4):301.
Hwang I, Lee JM, Lee KB, et al. Hepatic steatosis in living liver donor candidates: preoperative assessment by using breath-hold triple-echo MR imaging and 1H MR spectroscopy. Radiology. 2014;271(3):730-738.
Satkunasingham J, Nik HH, Fischer S, et al. Can negligible hepatic steatosis determined by magnetic resonance imaging-proton density fat fraction obviate the need for liver biopsy in potential liver donors? Liver Transpl. 2018;24(4):470-477.
Middleton MS, Heba ER, Hooker CA, et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis. Gastroenterology. 2017;153(3):753-761.
Caussy C, Brissot J, Singh S, et al. Prospective, same-day, direct comparison of controlled attenuation parameter with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging-proton density fat fraction as the standard. Clin Gastroenterol Hepatol. 2020;18(8):1842-1850.e6.
Emond JC, Fisher RA, Everson G, et al. Changes in liver and spleen volumes after living liver donation: a report from the adult-to-adult living donor liver transplantation cohort study (A2ALL). Liver Transpl. 2015;21(2):151-161.
Pomposelli JJ, Goodrich NP, Emond JC, et al. Patterns of early allograft dysfunction in adult live donor liver transplantation: the A2ALL experience. Transplantation. 2016;100(7):1490-1499.
Yen Y, Kuo F, Lin C, et al. Predicting hepatic steatosis in living liver donors via controlled attenuation parameter. Transplant Proc. 2018;50(10):3533-3538.
Hong YM, Yoon KT, Cho M, et al. Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant. Eur J Gastro Hepatol. 2017;29(7):805-810.